Business
PDS: Q1 Results and Clinical and Corporate Update
PDS: Q1 Results and Clinical and Corporate Update.
About this update from Emv Capital Plc
[{"type":"text","content":"\n\nFor immediate release\n \nEMV Capital plc\n \n(\"EMVC\" or the \"Company\")\n \nPDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update\n \nVERSATILE-003 Phase 3 Site Initiations Underway\n \nMultiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting\n \nEMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment group, reports that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) - a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, and in which it holds a 2.2% direct holding - has provided a clinical and corporate update and reported financial results for the first quarter ended March 31, 2025.\n \nFrank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, said:\n \n\"The first quarter of 2025 and recent weeks have been productive for PDS Biotech, highlighted by the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating Versamune® HPV in recurrent/metastatic (\"R/M\") HPV16-positive head and neck squamous carcinoma (\"HNSCC\"). We are pleased to announce that site activation is progressing, and that Mayo Clinic sites have recently been added to the trial. HPV16-positive HNSCC represents a large, rapidly growing patient population in need of targeted therapies to treat the underlying cause of the cancer, and our Versamune® HPV investigational therapy is currently the only targeted therapy in a Phase 3 trial specifically for HPV-16 positive tumours.\"\n \nClinical and Corporate Update\n· On April 23, 2025, PDS Biotech announced that three abstracts on Versamune® HPV (PDS0101) were selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30-June 3, 2025, in Chicago, IL.\n· On May 8, 2025, PDS Biotech announced that preclinical efficacy and immune response data with a novel investigational Infectimune® based universal flu vaccine were featured in two presentations on universal influenza vaccines, including an oral symposium at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, held May 3-7, 2025, in Honolulu, Hawaii.\n· &nbs...